首页> 外文期刊>British Journal of Cancer >Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
【24h】

Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

机译:七种肿瘤标志物在肺癌诊断中的临床评估:可以联合使用来改善结果吗?

获取原文
           

摘要

In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2) squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers (CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell lung cancer (94 cases). For comparison we also studied 66 patients with benign lung diseases and nine with pleural mesothelioma. NSE levels in SCLC patients were significantly higher than those in all the other groups studied. No significant variations were found among the SCC levels in all groups. CEA levels in patients with adenocarcinoma were significantly higher than those in all other groups studied. CYFRA 21-1 serum levels significantly increased in patients with squamous cell carcinoma and mesothelioma, while TPA, TPS and TPM increased in patients with lung cancer irrespective of the histological type. In patients with SCLC, high levels of all markers except SCC were found when the disease was extensive. In patients with non-SCLC, the highest levels of all tumour markers were usually found in those with advanced disease, although CYFRA 21-1 gave a sensitivity of 44% when a specificity of 95% was fixed in stage I non-SCLC patients. An analysis of receiver operating characteristic curves revealed that the highest diagnostic accuracies in distinguishing benign from malignant lung diseases were achieved with TPM (81%), CYFRA 21-1 (72%), CEA (78%) or TPA (78%) when using cut-off values of 46 Ul-1, 3.0 micrograms l-1, 2.0 micrograms l-1 and 75 Ul-1 respectively. When all patients were considered, the combined evaluation of more than one marker did not significantly improve the results obtained with TPM alone. However, taking into consideration the fact that CYFRA 21-1 is the most sensitive index of early lung tumours and that its combined determination with TPM did not worsen the overall sensitivity and specificity of the latter, the combined use of these two markers may be suggested as a useful took for the diagnosis of lung tumours.
机译:在这项研究中,我们比较了以下方面的诊断效用:(1)神经元特异性烯醇化酶(NSE); (2)鳞状细胞癌抗原(SCC); (3)癌胚抗原(CEA); (4)小细胞肺癌(SCLC)(21例)和非小细胞肺癌(94例)患者的细胞角蛋白标记(CYFRA 21-1,TPA,TPM,TPS)。为了进行比较,我们还研究了66例肺良性疾病患者和9例胸膜间皮瘤患者。 SCLC患者的NSE水平显着高于所有其他研究组。所有组的SCC水平之间均未发现显着差异。腺癌患者的CEA水平显着高于所有其他研究组。鳞癌和间皮瘤患者的CYFRA 21-1血清水平显着升高,而肺癌患者的TPA,TPS和TPM升高与组织学类型无关。在SCLC患者中,当疾病广泛时,发现除了SCC以外的所有其他标记物的含量都很高。在非SCLC患者中,尽管在I期非SCLC患者中固定了95%的特异性时,CYFRA 21-1的敏感性为44%,但通常在患有晚期疾病的患者中所有肿瘤标记物的水平最高。对接收器工作特征曲线的分析显示,在以下情况下,使用TPM(81%),CYFRA 21-1(72%),CEA(78%)或TPA(78%)可以实现区分良性和恶性肺部疾病的最高诊断准确性。使用分别为46 Ul-1、3.0微克l-1、2.0微克l-1和75 Ul-1的截断值。当考虑所有患者时,对一种以上标记物的综合评估并不能显着改善仅使用TPM获得的结果。但是,考虑到CYFRA 21-1是早期肺肿瘤的最敏感指标,并且将其与TPM联合测定并不会降低后者的整体敏感性和特异性,因此建议将这两种标记物组合使用作为诊断肺肿瘤的有用药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号